Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andy Karabajakian

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Cancers|April 23, 2022
Molecular Mechanisms of Kaposi Sarcoma DevelopmentAndy Karabajakian, Isabelle Ray-Coquard, Jean-Yves Blay
Future Oncology (London, England)|November 14, 2017
Nivolumab in recurrent/metastatic head and neck cancersAndy Karabajakian, Thibaut Reverdy, Max Gau, et al.
Frontiers in Oncology|March 15, 2021
Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck CancersSandra Ortiz-Cuaran, Jebrane Bouaoud, Andy Karabajakian, et al.
Bulletin Du Cancer|January 1, 2019
Thibaut Reverdy, Max Gau, Andy Karabajakian, et al.
Cancers|December 26, 2018
Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of BeliefAndy Karabajakian, Max Gau, Thibault Reverdy, et al.
Oral Oncology|July 27, 2019
Induction chemotherapy in head and neck cancers: Results and controversiesMax Gau, Andy Karabajakian, Thibaut Reverdy, et al.
Anti-Cancer Drugs|January 31, 2017
Chemotherapy for localized head and neck squamous cell cancersAndy Karabajakian, Philippe Toussaint, Eve-Marie Neidhardt, et al.
Anti-Cancer Drugs|February 7, 2017
Chemotherapy for recurrent/metastatic head and neck cancersAndy Karabajakian, Philippe Toussaint, Eve-Marie Neidhardt, et al.
Oral Oncology|January 13, 2024
Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypesYannick Le Meitour, Jean-Philippe Foy, Mathilde Guinand, et al.
Oncotarget|May 19, 2018
Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME scheduleAdeline Pêtre, Cécile Dalban, Andy Karabajakian, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Cancers|April 23, 2022
Molecular Mechanisms of Kaposi Sarcoma DevelopmentAndy Karabajakian, Isabelle Ray-Coquard, Jean-Yves Blay
Future Oncology (London, England)|November 14, 2017
Nivolumab in recurrent/metastatic head and neck cancersAndy Karabajakian, Thibaut Reverdy, Max Gau, et al.
Frontiers in Oncology|March 15, 2021
Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck CancersSandra Ortiz-Cuaran, Jebrane Bouaoud, Andy Karabajakian, et al.
Bulletin Du Cancer|January 1, 2019
Thibaut Reverdy, Max Gau, Andy Karabajakian, et al.
Cancers|December 26, 2018
Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of BeliefAndy Karabajakian, Max Gau, Thibault Reverdy, et al.
Oral Oncology|July 27, 2019
Induction chemotherapy in head and neck cancers: Results and controversiesMax Gau, Andy Karabajakian, Thibaut Reverdy, et al.
Anti-Cancer Drugs|January 31, 2017
Chemotherapy for localized head and neck squamous cell cancersAndy Karabajakian, Philippe Toussaint, Eve-Marie Neidhardt, et al.
Anti-Cancer Drugs|February 7, 2017
Chemotherapy for recurrent/metastatic head and neck cancersAndy Karabajakian, Philippe Toussaint, Eve-Marie Neidhardt, et al.
Oral Oncology|January 13, 2024
Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypesYannick Le Meitour, Jean-Philippe Foy, Mathilde Guinand, et al.
Oncotarget|May 19, 2018
Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME scheduleAdeline Pêtre, Cécile Dalban, Andy Karabajakian, et al.
Pageof 2